Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.

Journal of hepatology - 1 Apr 2017

Wyles David, Dvory-Sobol Hadas, Svarovskaia Evguenia S, Doehle Brian P, Martin Ross, Afdhal Nezam H, Kowdley Kris V, Lawitz Eric, Brainard Diana M, Miller Michael D, Mo Hongmei, Gane Edward J

Abstract excerpt

BACKGROUND & AIMS: Ledipasvir/sofosbuvir combination treatment in phase III clinical trials resulted in sustained viral suppression in 94-99% of patients. This study characterized drug resistance in treatment failures, which may help to inform retreatment options. METHODS: We performed NS5A and NS5B deep sequencing of hepatitis C virus (HCV) from patients infected with genotype (GT) 1 who participated in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Fluorenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Viral

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Treatment Failure

Share to Uridine Monophosphate

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 27923693
DOI: 10.1016/j.jhep.2016.11.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.PMID 27923693Read ↗

Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.Semantic proximity Read ↗

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.Semantic proximity Read ↗

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.Semantic proximity Read ↗

Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.Semantic proximity Read ↗

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.Semantic proximity Read ↗

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.Semantic proximity Read ↗

Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.Semantic proximity Read ↗

Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.Semantic proximity Read ↗

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.Semantic proximity Read ↗

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.Semantic proximity Read ↗

Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.